EU/3/05/321

Table of contents

About

Please note that this product was withdrawn from the Community register of designated orphan medicinal products in February 2013 on request of the sponsor.

On 28 October 2005, orphan designation (EU/3/05/321) was granted by the European Commission to Orphix Consulting GmbH, Germany, for (1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R, 12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34, 34a-tetra-cosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propyl}-2-methoxy-cyclohexyldimethyl-phosphinate (also known as 'AP23573') for the treatment of primary malignant bone tumours.

The sponsorship was transferred to Merck Sharp & Dohme Limited, United Kingdom, in January 2009.

Key facts

Active substance
(1R, 2R, 4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R, 27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetra-cosahydro-3H-23,2
Disease / condition
Treatment of primary malignant bone tumours
Date of decision
28/10/2005
Outcome
Withdrawn
Orphan decision number
EU/3/05/321

Sponsor's contact details

Merck Sharp & Dohme Limited
Hertford Road
Hoddesdon
Hertfordshire
EN11 9BU
United Kingdom
Tel. +44 (0)1992 452206
Fax +44 (0)1992 507206
E-mail: externalaffairs_uk@merck.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating